Adial Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense, after Tax
Adial Pharmaceuticals, Inc. (ADIL) reported Share-based Payment Arrangement, Expense, after Tax of $309.84 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax · last filed 2021-03-22
- Adial Pharmaceuticals, Inc. share-based payment arrangement, expense, after tax for fiscal 2020 was $309.84K, a 16.75% decline from fiscal 2019.
- Adial Pharmaceuticals, Inc. share-based payment arrangement, expense, after tax for fiscal 2019 was $372.19K.
| Period end | Share-based Payment Arrangement, Expense, after Tax 12 month |
|---|---|
| 2020-12-31 | $309.84K 10-K · filed 2021-03-22 |
| 2019-12-31 | $372.19K 10-K · filed 2021-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |